Provectus Biopharmaceuticals Inc PVCT
$0.05 $0.00 (2.10%) 1D
Last Updated: Sep 10, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Provectus Biopharmaceuticals Inc Stock Halal?
Shariah Compliance Analysis of PVCT Stock
United States Health Care Nano Cap Yes. As of September 2026, Provectus Biopharmaceuticals Inc (PVCT) is classified as HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Provectus Biopharmaceuticals Inc passes Musaffa's business and financial screening criteria.
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. The company is headquartered in Knoxville, Tennessee and currently employs 6 full-time employees. The company went IPO on 2000-04-07. The firm is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
PVCT Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Provectus Biopharmaceuticals Inc is classified as halal.
HALAL
Report Source: undefined Quarter Report
Provectus Biopharmaceuticals Inc (PVCT) Chart
Financial Metrics & Statements of Provectus Biopharmaceuticals Inc (PVCT)
FAQ's for Provectus Biopharmaceuticals Inc (PVCT)
- As of September 2026, Provectus Biopharmaceuticals Inc PVCT is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Provectus Biopharmaceuticals Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Provectus Biopharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Provectus Biopharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Provectus Biopharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Provectus Biopharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to Provectus Biopharmaceuticals Inc (PVCT)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
